{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:12:23Z","timestamp":1788667943317,"version":"build-2803163510"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Province Pioneer Research and Development Project.","award":["No.2025C02092"],"award-info":[{"award-number":["No.2025C02092"]}]},{"name":"Zhejiang Province Pioneer Research and Development Project","award":["No. 2025C02094"],"award-info":[{"award-number":["No. 2025C02094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01842-2","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:17:58Z","timestamp":1788617878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances"],"prefix":"10.1186","volume":"19","author":[{"given":"Yufang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"8","key":"1842_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.trecan.2025.04.014","volume":"11","author":"P Berraondo","year":"2025","unstructured":"Berraondo P, Cuesta R, Aranda F, Martinez-Ria\u00f1o A, Eguren-Santamaria I, Luri-Rey C, et al. Immunocytokines and cytokine neutralization for cancer immunotherapy. Trends Cancer. 2025;11(8):790\u2013805. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.014.","journal-title":"Trends Cancer"},{"issue":"18 Pt 2","key":"1842_CR2","doi-asserted-by":"publisher","first-page":"S6342","DOI":"10.1158\/1078-0432.CCR-040029","volume":"10","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(18 Pt 2):S6342\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-040029.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"1842_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18869\/acadpub.ibj.21.2.77","volume":"21","author":"E Adabi","year":"2017","unstructured":"Adabi E, Saebi F, Moradi Hasan-Abad A, Teimoori-Toolabi L, Kardar GA. Evaluation of an albumin-binding domain protein fused to recombinant human IL-2 and its effects on the bioactivity and serum half-life of the cytokine. Iran Biomed J. 2017;21(2):77\u201383. https:\/\/doi.org\/10.18869\/acadpub.ibj.21.2.77.","journal-title":"Iran Biomed J"},{"issue":"9","key":"1842_CR4","doi-asserted-by":"publisher","first-page":"e002865","DOI":"10.1136\/jitc-2021-002865","volume":"9","author":"R Hernandez","year":"2021","unstructured":"Hernandez R, LaPorte KM, Hsiung S, Santos Savio A, Malek TR. High-dose IL-2\/CD25 fusion protein amplifies vaccine-induced CD4\u2009+\u2009and CD8\u2009+\u2009neoantigen-specific T cells to promote antitumor immunity. J Immunother Cancer. 2021;9(9):e002865. https:\/\/doi.org\/10.1136\/jitc-2021-002865.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1842_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez R, P\u00f5der J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22(10):614\u201328. https:\/\/doi.org\/10.1038\/s41577-022-00680-w.","journal-title":"Nat Rev Immunol"},{"issue":"8036","key":"1842_CR6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41586-024-08087-4","volume":"634","author":"CK Mo","year":"2024","unstructured":"Mo CK, Liu J, Chen S, Storrs E, Targino da Costa ALN, Houston A, et al. Tumor evolution and microenvironment interactions in 2D and 3D space. Nature. 2024;634(8036):1178\u201386. https:\/\/doi.org\/10.1038\/s41586-024-08087-4.","journal-title":"Nature"},{"issue":"1","key":"1842_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98. https:\/\/doi.org\/10.1186\/s13045-021-01103-4.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1842_CR8","doi-asserted-by":"publisher","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","volume":"10","author":"JX Lin","year":"2018","unstructured":"Lin JX, Leonard WJ. The common cytokine receptor \u03b3 chain family of cytokines. Cold Spring Harb Perspect Biol. 2018;10(9):a028449. https:\/\/doi.org\/10.1101\/cshperspect.a028449.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1842_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411\u201333. https:\/\/doi.org\/10.1146\/annurev-immunol-042617-053352.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1842_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","volume":"5","author":"B Zhang","year":"2021","unstructured":"Zhang B, Sun J, Wang Y, Ji D, Yuan Y, Li S, et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat Biomed Eng. 2021;5(11):1288\u2013305. https:\/\/doi.org\/10.1038\/s41551-021-00797-8.","journal-title":"Nat Biomed Eng"},{"issue":"5068","key":"1842_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1126\/science.1631562","volume":"257","author":"JF Bazan","year":"1992","unstructured":"Bazan JF. Unraveling the structure of IL-2. Science. 1992;257(5068):410\u20133. https:\/\/doi.org\/10.1126\/science.1631562.","journal-title":"Science"},{"issue":"9","key":"1842_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu W, Chia T, Lu J, Li X, Guan J, Li Y, et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25\u2009+\u2009CD8+ T cells. Nat Cancer. 2023;4(9):14\u201353. https:\/\/doi.org\/10.1038\/s43018-023-00612-0.","journal-title":"Nat Cancer"},{"key":"1842_CR13","doi-asserted-by":"publisher","unstructured":"Losey HC, Lopes JE, Dean RL, Huff MR, Moroso RA, Alvarez JC. Efficacy of ALKS 4230, a novel immunotherapeutic agent, in murine syngeneic tumor models alone and in combination with immune checkpoint inhibitors. Cancer Res. 2017;77(13 Suppl):591. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-591.","DOI":"10.1158\/1538-7445.AM2017-591"},{"issue":"12","key":"1842_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763\u201377. https:\/\/doi.org\/10.1016\/j.it.2015.10.003.","journal-title":"Trends Immunol"},{"issue":"1","key":"1842_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43(1):15\u201335. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.011.","journal-title":"Cancer Cell"},{"issue":"5751","key":"1842_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","volume":"310","author":"X Wang","year":"2005","unstructured":"Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and \u03b3(c) receptors. Science. 2005;310(5751):1159\u201363. https:\/\/doi.org\/10.1126\/science.1117893.","journal-title":"Science"},{"issue":"8","key":"1842_CR17","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1073\/pnas.0511161103","volume":"103","author":"DJ Stauber","year":"2006","unstructured":"Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006;103(8):2788. https:\/\/doi.org\/10.1073\/pnas.0511161103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1842_CR18","doi-asserted-by":"publisher","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2017","unstructured":"Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology. 2017;6(3):e1277306. https:\/\/doi.org\/10.1080\/2162402X.2016.1277306.","journal-title":"OncoImmunology"},{"issue":"1","key":"1842_CR19","doi-asserted-by":"publisher","first-page":"e003155","DOI":"10.1136\/jitc-2021-003155","volume":"10","author":"R Merchant","year":"2022","unstructured":"Merchant R, Galligan C, Munegowda MA, Pearce LB, Lloyd P, Smith P, et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. J Immunother Cancer. 2022;10(1):e003155. https:\/\/doi.org\/10.1136\/jitc-2021-003155.","journal-title":"J Immunother Cancer"},{"key":"1842_CR20","doi-asserted-by":"publisher","unstructured":"Ye F, Huang Z, Cheng L, Huang J, Chen S, Hua M, et al. A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy. Regular and Young Investigator Award Abstracts. 2022;A1147-A1147. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1104.","DOI":"10.1136\/jitc-2022-SITC2022.1104"},{"issue":"10","key":"1842_CR21","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/jimmun\/vkaf142","volume":"214","author":"L Ma","year":"2025","unstructured":"Ma L, Acuff NV, Ptacin JL, Caffaro CE, San Jose KM, Aerni HR, et al. SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity. J Immunol. 2025;214(10):2781\u201395. https:\/\/doi.org\/10.1093\/jimmun\/vkaf142.","journal-title":"J Immunol"},{"issue":"6 Suppl","key":"1842_CR22","doi-asserted-by":"publisher","first-page":"TPS596","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS596","volume":"40","author":"P Grivas","year":"2022","unstructured":"Grivas P, Van Der Heijden MS, Necchi A, Siefker-Radtke AO, Cutuli H, Qureshi AH, et al. PIVOT IO 009: a phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. J Clin Oncol. 2022;40(6 Suppl):TPS596\u2013596. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS596.","journal-title":"J Clin Oncol"},{"key":"1842_CR23","doi-asserted-by":"publisher","first-page":"S886","DOI":"10.1016\/j.annonc.2022.07.875","volume":"33","author":"H L\u00e4ubli","year":"2022","unstructured":"L\u00e4ubli H, Alonso G, Lopez JS, Calvo E, Joerger M, Perez V, et al. 749P ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I\/II study. Ann Oncol. 2022;33:S886\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.875.","journal-title":"Ann Oncol"},{"key":"1842_CR24","doi-asserted-by":"publisher","unstructured":"Murer P, Salazar U, Egli N, Petersen L, Neubert P, Stocker C, et al. ANV600 is a novel PD-1-targeted IL-2R\u03b2\/\u03b3 agonist that is combinable with therapeutic PD-1 inhibitors. Regular and Young Investigator Award Abstracts. 2023;A918-A918. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0820.","DOI":"10.1136\/jitc-2023-SITC2023.0820"},{"key":"1842_CR25","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/S0090-8258(22)01548-7","volume":"166","author":"T Herzog","year":"2022","unstructured":"Herzog T, Moore K, Konstantinopoulos P, Gilbert L, Hays J, Monk B, et al. ARTISTRY-7: a phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326). Gynecol Oncol. 2022;166:S169. https:\/\/doi.org\/10.1016\/S0090-8258(22)01548-7.","journal-title":"Gynecol Oncol"},{"issue":"30","key":"1842_CR26","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1200\/JCO.23.00172","volume":"41","author":"A Diab","year":"2023","unstructured":"Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, et al. Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results. J Clin Oncol. 2023;41(30):4756\u201367. https:\/\/doi.org\/10.1200\/JCO.23.00172.","journal-title":"J Clin Oncol"},{"key":"1842_CR27","doi-asserted-by":"publisher","unstructured":"To M, Merchant N, Coello M, Galligan C, Mehta K, Atkinson V, et al. Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist. Regular and Young Investigator Award Abstracts. 2022;A776-A776. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0743.","DOI":"10.1136\/jitc-2022-SITC2022.0743"},{"key":"1842_CR28","doi-asserted-by":"publisher","first-page":"1537466","DOI":"10.3389\/fimmu.2025.1537466","volume":"16","author":"F Ye","year":"2025","unstructured":"Ye F, Huang J, Cheng X, Chen SC, Huang F, Huang WC, et al. AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 cis-activation for enhanced anti-tumor immunity and diminished toxicity. Front Immunol. 2025;16:1537466. https:\/\/doi.org\/10.3389\/fimmu.2025.1537466.","journal-title":"Front Immunol"},{"issue":"1","key":"1842_CR29","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","volume":"12","author":"JL Ptacin","year":"2021","unstructured":"Ptacin JL, Caffaro CE, Ma L, San Jose Gall KM, Aerni HR, Acuff NV, et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat Commun. 2021;12(1):4785. https:\/\/doi.org\/10.1038\/s41467-021-24987-9.","journal-title":"Nat Commun"},{"issue":"10","key":"1842_CR30","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/2767-9764.CRC-24-0278","volume":"4","author":"L Ma","year":"2024","unstructured":"Ma L, Acuff NV, Joseph IB, Ptacin JL, Caffaro CE, San Jose KM, et al. A precision engineered interleukin-2 for bolstering CD8\u2009+\u2009T- and NK-cell activity without eosinophilia and vascular leak syndrome in nonhuman primates. Cancer Res Commun. 2024;4(10):2799\u2013814. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0278.","journal-title":"Cancer Res Commun"},{"issue":"3","key":"1842_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):681\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1631.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1842_CR32","doi-asserted-by":"publisher","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 2017;12(7):e0179431. https:\/\/doi.org\/10.1371\/journal.pone.0179431.","journal-title":"PLoS ONE"},{"issue":"6","key":"1842_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","volume":"9","author":"SE Bentebibel","year":"2019","unstructured":"Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1495.","journal-title":"Cancer Discov"},{"issue":"1","key":"1842_CR34","doi-asserted-by":"publisher","first-page":"2381891","DOI":"10.1080\/19420862.2024.2381891","volume":"16","author":"P Murer","year":"2024","unstructured":"Murer P, Brannetti B, Rondeau JM, Petersen L, Egli N, Popp S, et al. Discovery and development of ANV419, an IL-2\/anti-IL-2 antibody fusion protein with potent CD8\u2009+\u2009T and natural killer cell-stimulating capacity for cancer immunotherapy. mAbs. 2024;16(1):2381891. https:\/\/doi.org\/10.1080\/19420862.2024.2381891.","journal-title":"mAbs"},{"issue":"11","key":"1842_CR35","doi-asserted-by":"publisher","first-page":"e007784","DOI":"10.1136\/jitc-2023-007784","volume":"11","author":"M Joerger","year":"2023","unstructured":"Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, De La Corral E, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed\/refractory advanced solid tumors. J Immunother Cancer. 2023;11(11):e007784. https:\/\/doi.org\/10.1136\/jitc-2023-007784.","journal-title":"J Immunother Cancer"},{"key":"1842_CR36","doi-asserted-by":"publisher","unstructured":"Huber C, Alonso G, Garralda E, Bucher C, Jacqmin P, Katopodis A, et al. Favorable pre-clinical safety profile of the novel not-alpha IL-2 agonist ANV419 supports first-in-human clinical development. Regular and Young Investigator Award Abstracts. 2021;A731-A731. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.703.","DOI":"10.1136\/jitc-2021-SITC2021.703"},{"issue":"7","key":"1842_CR37","doi-asserted-by":"publisher","first-page":"e011905","DOI":"10.1136\/jitc-2025-011905","volume":"13","author":"P Murer","year":"2025","unstructured":"Murer P, Petersen L, Egli N, Salazar U, Neubert P, Zurbach A, et al. ANV600 is a novel PD-1 targeted IL-2R\u03b2\u03b3 agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy. J Immunother Cancer. 2025;13(7):e011905. https:\/\/doi.org\/10.1136\/jitc-2025-011905.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1842_CR38","doi-asserted-by":"publisher","first-page":"e000673","DOI":"10.1136\/jitc-2020-000673","volume":"8","author":"JE Lopes","year":"2020","unstructured":"Lopes JE, Fisher JL, Flick HL, Wang C, Sun L, Ernstoff MS, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020;8(1):e000673. https:\/\/doi.org\/10.1136\/jitc-2020-000673.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1842_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1124\/jpet.121.000612","volume":"379","author":"JE Lopes","year":"2021","unstructured":"Lopes JE, Sun L, Flick HL, Murphy EA, Losey HC. Pharmacokinetics and pharmacodynamic effects of nemvaleukin alfa, a selective agonist of the intermediate-affinity IL-2 receptor, in cynomolgus monkeys. J Pharmacol Exp Ther. 2021;379(2):203\u201310. https:\/\/doi.org\/10.1124\/jpet.121.000612.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1842_CR40","doi-asserted-by":"publisher","first-page":"e010143","DOI":"10.1136\/jitc-2024-0101431136\/jitc-2024-010143","volume":"12","author":"UN Vaishampayan","year":"2024","unstructured":"Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, et al. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). J Immunother Cancer. 2024;12(11):e010143. https:\/\/doi.org\/10.1136\/jitc-2024-0101431136\/jitc-2024-010143.","journal-title":"J Immunother Cancer"},{"issue":"16 Suppl","key":"1842_CR41","doi-asserted-by":"publisher","first-page":"9562","DOI":"10.1200\/JCO.2024.42.16_suppl.9562","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Lin J, Wang H, Zhang W, Liang X, Cui J, et al. First-in-class PD-1\/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: safety and efficacy results from a phase I study. J Clin Oncol. 2024;42(16 Suppl):9562\u20139562. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9562.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1842_CR42","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ni.2449","volume":"13","author":"AM Ring","year":"2012","unstructured":"Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, et al. Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15. Nat Immunol. 2012;13(12):1187\u201395. https:\/\/doi.org\/10.1038\/ni.2449.","journal-title":"Nat Immunol"},{"issue":"1\u20132","key":"1842_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cyto.2009.07.442","volume":"48","author":"A Bessard","year":"2009","unstructured":"Bessard A, Sol\u00e9 V, Bouchaud G, Qu\u00e9m\u00e9ner A, Jacques Y. High antitumor activity of RLI, an IL15-IL15Ralpha fusion protein, in metastatic melanoma and colorectal cancer. Cytokine. 2009;48(1\u20132):105. https:\/\/doi.org\/10.1016\/j.cyto.2009.07.442.","journal-title":"Cytokine"},{"issue":"13 Suppl","key":"1842_CR44","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1158\/1538-7445.AM2018-3775","volume":"78","author":"I Adkins","year":"2018","unstructured":"Adkins I, Sadilkova L, Hradilova N, Tomala J, Tomalova B, Kovar M, et al. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Res. 2018;78(13 Suppl):3775\u20133775. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-3775.","journal-title":"Cancer Res"},{"key":"1842_CR45","doi-asserted-by":"publisher","first-page":"106450","DOI":"10.1016\/j.ejps.2023.106450","volume":"186","author":"D Lu","year":"2023","unstructured":"Lu D, Yadav R, Holder P, Chiang E, Sanjabi S, Poon V, et al. Complex PK-PD of an engineered IL-15\/IL-15R\u03b1-fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics. Eur J Pharm Sci. 2023;186:106450. https:\/\/doi.org\/10.1016\/j.ejps.2023.106450.","journal-title":"Eur J Pharm Sci"},{"issue":"12 Suppl","key":"1842_CR46","doi-asserted-by":"publisher","first-page":"CT040","DOI":"10.1158\/1538-7445.AM2022-CT040","volume":"82","author":"S Champiat","year":"2022","unstructured":"Champiat S, Marabelle A, Galvao V, LoRusso P, Grell P, Cassier P, et al. SOT101, an IL-2\/IL-15 Rbetagamma superagonist, in combination with pembrolizumab in patients with advanced solid tumors: interim safety and efficacy results from the AURELIO-03 dose escalation trial. Cancer Res. 2022;82(12 Suppl):CT040\u2013040. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-CT040.","journal-title":"Cancer Res"},{"issue":"6","key":"1842_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/d41573-024-00073-9","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer. Nat Rev Drug Discov. 2024;23(6):410\u2013410. https:\/\/doi.org\/10.1038\/d41573-024-00073-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1842_CR48","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-21-0058","volume":"9","author":"Y Xu","year":"2021","unstructured":"Xu Y, Carrascosa LC, Yeung YA, Chu MLH, Yang W, Djuretic I, et al. An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity. Cancer Immunol Res. 2021;9(10):1141\u201357. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0058.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1842_CR49","doi-asserted-by":"publisher","first-page":"e0298240","DOI":"10.1371\/journal.pone.0298240","volume":"19","author":"C Ji","year":"2024","unstructured":"Ji C, Kuang B, Buetow BS, Vitsky A, Xu Y, Huang TH, et al. Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys. PLoS ONE. 2024;19(2):e0298240. https:\/\/doi.org\/10.1371\/journal.pone.0298240.","journal-title":"PLoS ONE"},{"issue":"7","key":"1842_CR50","doi-asserted-by":"publisher","first-page":"e132000","DOI":"10.1172\/jci.insight.132000","volume":"5","author":"S Deng","year":"2020","unstructured":"Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, et al. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8\u2009+\u2009T cells. JCI Insight. 2020;5(7):e132000. https:\/\/doi.org\/10.1172\/jci.insight.132000.","journal-title":"JCI Insight"},{"issue":"6","key":"1842_CR51","doi-asserted-by":"publisher","first-page":"112657","DOI":"10.1016\/j.celrep.2023.112657","volume":"42","author":"GC Abhiraman","year":"2023","unstructured":"Abhiraman GC, Bruun TUJ, Caveney NA, Su LL, Saxton RA, Yin Q, et al. A structural blueprint for interleukin-21 signal modulation. Cell Rep. 2023;42(6):112657. https:\/\/doi.org\/10.1016\/j.celrep.2023.112657.","journal-title":"Cell Rep"},{"issue":"4","key":"1842_CR52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","volume":"50","author":"WJ Leonard","year":"2019","unstructured":"Leonard WJ, Lin JX, O\u2019Shea JJ. The \u03b3c family of cytokines: basic biology to therapeutic ramifications. Immunity. 2019;50(4):832\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.028.","journal-title":"Immunity"},{"key":"1842_CR53","doi-asserted-by":"publisher","first-page":"FFacultyRev1000","DOI":"10.12688\/f1000research.7634.1","volume":"5","author":"WJ Leonard","year":"2016","unstructured":"Leonard WJ, Wan CK. IL-21 signaling in immunity. F1000Research. 2016;5:FFacultyRev1000\u2013224. https:\/\/doi.org\/10.12688\/f1000research.7634.1.","journal-title":"F1000Research"},{"key":"1842_CR54","doi-asserted-by":"publisher","first-page":"832454","DOI":"10.1155\/2010\/832454","volume":"2010","author":"M Xu","year":"2010","unstructured":"Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol. 2010;2010:832454. https:\/\/doi.org\/10.1155\/2010\/832454.","journal-title":"Clin Dev Immunol"},{"issue":"10","key":"1842_CR55","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.str.2024.07.010","volume":"32","author":"H Chen","year":"2024","unstructured":"Chen H, Ge X, Li C, Zeng J, Wang X. Structure and assembly of the human IL-12 signaling complex. Structure. 2024;32(10):1641\u2013e16515. https:\/\/doi.org\/10.1016\/j.str.2024.07.010.","journal-title":"Structure"},{"issue":"4","key":"1842_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","volume":"50","author":"ED Tait Wojno","year":"2019","unstructured":"Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50(4):851\u201370. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.011.","journal-title":"Immunity"},{"issue":"7","key":"1842_CR57","doi-asserted-by":"publisher","first-page":"e1438800","DOI":"10.1080\/2162402X.2018.1438800","volume":"7","author":"K Jung","year":"2018","unstructured":"Jung K, Ha JH, Kim JE, Kim JA, Kim YJ, Kim CH, et al. Heterodimeric fc-fused IL12 shows potent antitumor activity by generating memory CD8\u2009+\u2009T cells. Oncoimmunology. 2018;7(7):e1438800. https:\/\/doi.org\/10.1080\/2162402X.2018.1438800.","journal-title":"Oncoimmunology"},{"issue":"8 Suppl 1","key":"1842_CR58","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1538-7445.AM2025-3425","volume":"85","author":"J Guo","year":"2025","unstructured":"Guo J, Ding J, Gu C, Ye L, Zhu D, Ou Y, et al. A novel anti-EGFR x IL-10\u00a0M (FP010) fusion protein for solid tumor therapy. Cancer Res. 2025;85(8 Suppl 1):3425\u20133425. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3425.","journal-title":"Cancer Res"},{"issue":"6","key":"1842_CR59","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell. 2011;20(6):781\u201396. https:\/\/doi.org\/10.1016\/j.ccr.2011.11.003.","journal-title":"Cancer Cell"},{"issue":"6","key":"1842_CR60","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8\u2009+\u2009T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22(6):746\u201356. https:\/\/doi.org\/10.1038\/s41590-021-00940-2.","journal-title":"Nat Immunol"},{"issue":"2","key":"1842_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.yexcr.2019.03.038","volume":"379","author":"C Li","year":"2019","unstructured":"Li C, Zuo W. IL-10 in vitro could enhance IFN\u03b3 expression and suppress PD-1 expression in CD8 T cells from esophageal cancer patients. Exp Cell Res. 2019;379(2):159\u201365. https:\/\/doi.org\/10.1016\/j.yexcr.2019.03.038.","journal-title":"Exp Cell Res"},{"issue":"6535","key":"1842_CR62","doi-asserted-by":"publisher","first-page":"eabc8433","DOI":"10.1126\/science.abc8433","volume":"371","author":"RA Saxton","year":"2021","unstructured":"Saxton RA, Tsutsumi N, Su LL, Abhiraman GC, Mohan K, Henneberg LT, et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science. 2021;371(6535):eabc8433. https:\/\/doi.org\/10.1126\/science.abc8433.","journal-title":"Science"},{"issue":"1","key":"1842_CR63","doi-asserted-by":"publisher","first-page":"102515","DOI":"10.1016\/j.xcrm.2025.102515","volume":"7","author":"C Gu","year":"2026","unstructured":"Gu C, Guo J, Zhou C, Hu P, Wu X, Ding J, et al. An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. Cell Rep Med. 2026;7(1):102515. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102515.","journal-title":"Cell Rep Med"},{"issue":"5","key":"1842_CR64","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8\u2009+\u2009T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell. 2018;34(5):775\u2013e7913. https:\/\/doi.org\/10.1016\/j.ccell.2018.10.007.","journal-title":"Cancer Cell"},{"issue":"18","key":"1842_CR65","doi-asserted-by":"publisher","first-page":"13552","DOI":"10.1074\/jbc.275.18.13552","volume":"275","author":"K Josephson","year":"2000","unstructured":"Josephson K, DiGiacomo R, Indelicato SR, Iyo AH, Nagabhushan TL, Parker MH, et al. Design and analysis of an engineered human interleukin-10 monomer. J Biol Chem. 2000;275(18):13552\u20137. https:\/\/doi.org\/10.1074\/jbc.275.18.13552.","journal-title":"J Biol Chem"},{"issue":"6","key":"1842_CR66","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","volume":"35","author":"J Qiao","year":"2019","unstructured":"Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8\u2009+\u2009T cell apoptosis. Cancer Cell. 2019;35(6):901\u2013e9154. https:\/\/doi.org\/10.1016\/j.ccell.2019.05.005.","journal-title":"Cancer Cell"},{"key":"1842_CR67","doi-asserted-by":"publisher","first-page":"102413","DOI":"10.1016\/j.coi.2024.102413","volume":"86","author":"NA de Weerd","year":"2024","unstructured":"de Weerd NA, Kurowska AK, Mendoza JL, Schreiber G. Structure-function of type I and III interferons. Curr Opin Immunol. 2024;86:102413. https:\/\/doi.org\/10.1016\/j.coi.2024.102413.","journal-title":"Curr Opin Immunol"},{"key":"1842_CR68","doi-asserted-by":"publisher","first-page":"606489","DOI":"10.3389\/fimmu.2020.606489","volume":"11","author":"MR Walter","year":"2020","unstructured":"Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11:606489. https:\/\/doi.org\/10.3389\/fimmu.2020.606489.","journal-title":"Front Immunol"},{"issue":"1","key":"1842_CR69","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s43556-025-00381-5","volume":"6","author":"C Wen","year":"2025","unstructured":"Wen C, Lan Q, Wang Y, Ni Y, Wong AST, Liu D. Interferon signaling pathways in health and disease. Mol Biomed. 2025;6(1):135. https:\/\/doi.org\/10.1186\/s43556-025-00381-5.","journal-title":"Mol Biomed"},{"key":"1842_CR70","doi-asserted-by":"publisher","unstructured":"Park H, Song JW, Lee HK, Seo MR, Ryu S, Kim RE, et al. ABN202 (\u03b1TROP2): a TROP2-targeting IFN-\u03b2 mutein fusion protein with retained activity in acidic tumor microenvironments and reduced toxicity for an improved therapeutic window. J Immunother Cancer. 2025;13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.08651136\/jitc-2025-SITC2025.0865.","DOI":"10.1136\/jitc-2025-SITC2025.08651136\/jitc-2025-SITC2025.0865"},{"issue":"12","key":"1842_CR71","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20(12):1574\u201383. https:\/\/doi.org\/10.1038\/s41590-019-0466-2.","journal-title":"Nat Immunol"},{"issue":"23","key":"1842_CR72","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.3390\/ijms262311679","volume":"26","author":"K Vorona","year":"2025","unstructured":"Vorona K, Ryapolova A, Sokolova O, Karabelsky A, Ivanov R, Reshetnikov V, et al. Interferon-based therapeutics in cancer therapy: past, present, and future. Int J Mol Sci. 2025;26(23):11679. https:\/\/doi.org\/10.3390\/ijms262311679.","journal-title":"Int J Mol Sci"},{"issue":"8Supplement1","key":"1842_CR73","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1538-7445.AM2025-3416","volume":"85","author":"M Rapp","year":"2025","unstructured":"Rapp M, Duerr H, Schnetzler G, Bertoldo D, Bates J, Kruempelmann L, et al. Abstract 3416: advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744. Cancer Res. 2025;85(8Supplement1):3416. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3416.","journal-title":"Cancer Res"},{"issue":"1","key":"1842_CR74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2023.12.010","volume":"42","author":"ME Hoekstra","year":"2024","unstructured":"Hoekstra ME, Slagter M, Urbanus J, Toebes M, Slingerland N, de Rink I, et al. Distinct spatiotemporal dynamics of CD8\u2009+\u2009T cell-derived cytokines in the tumor microenvironment. Cancer Cell. 2024;42(1):157\u2013e1679. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.010.","journal-title":"Cancer Cell"},{"key":"1842_CR75","doi-asserted-by":"publisher","first-page":"1267918","DOI":"10.3389\/fimmu.2023.1267918","volume":"14","author":"H Luo","year":"2023","unstructured":"Luo H, Wang W, Mai J, Yin R, Cai X, Li Q. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment. Front Immunol. 2023;14:1267918. https:\/\/doi.org\/10.3389\/fimmu.2023.1267918.","journal-title":"Front Immunol"},{"issue":"2","key":"1842_CR76","doi-asserted-by":"publisher","first-page":"e70023","DOI":"10.1002\/mog2.70023","volume":"4","author":"XH Ding","year":"2025","unstructured":"Ding XH, Li XP, Chen F, Wang H, Jiang YZ. Unlocking T-cell plasticity in the tumor microenvironment: implications for cancer progression and therapeutic strategies. MedComm Oncol. 2025;4(2):e70023. https:\/\/doi.org\/10.1002\/mog2.70023.","journal-title":"MedComm Oncol"},{"key":"1842_CR77","doi-asserted-by":"publisher","first-page":"619195","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, et al. IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front Immunol. 2021;12:619195. https:\/\/doi.org\/10.3389\/fimmu.2021.619195.","journal-title":"Front Immunol"},{"issue":"2","key":"1842_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","volume":"3","author":"SL Meier","year":"2022","unstructured":"Meier SL, Satpathy AT, Wells DK. Bystander T cells in cancer immunology and therapy. Nat Cancer. 2022;3(2):143\u201355. https:\/\/doi.org\/10.1038\/s43018-022-00335-8.","journal-title":"Nat Cancer"},{"issue":"1","key":"1842_CR79","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. https:\/\/doi.org\/10.1038\/s41467-018-05072-0.","journal-title":"Nat Commun"},{"key":"1842_CR80","doi-asserted-by":"publisher","first-page":"1476904","DOI":"10.3389\/fimmu.2024.1476904","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Liu J, Mo Y, Zhang K, Huang B, Shang D. CD8\u2009+\u2009T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15:1476904. https:\/\/doi.org\/10.3389\/fimmu.2024.1476904.","journal-title":"Front Immunol"},{"issue":"5","key":"1842_CR81","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/2326-6066.CIR-24-0894","volume":"13","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang C, Jiang A, Lin A, Zhu L, Mou W, et al. T-cell senescence in the tumor microenvironment. Cancer Immunol Res. 2025;13(5):618\u201332. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0894.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"1842_CR82","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8\u2009+\u2009tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246\u201359. https:\/\/doi.org\/10.1172\/JCI73639.","journal-title":"J Clin Invest"},{"issue":"7","key":"1842_CR83","doi-asserted-by":"publisher","first-page":"e010672","DOI":"10.1136\/jitc-2024-010672","volume":"13","author":"M Dysthe","year":"2025","unstructured":"Dysthe M, Navin I, van Leeuwen D, Pineda J, Baumgartner C, Rooney CM, et al. Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control. J Immunother Cancer. 2025;13(7):e010672. https:\/\/doi.org\/10.1136\/jitc-2024-010672.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1842_CR84","doi-asserted-by":"publisher","first-page":"189471","DOI":"10.1016\/j.bbcan.2025.189471","volume":"1880","author":"S Ghosh","year":"2025","unstructured":"Ghosh S, Dutta R, Goswami D, Ghatak D, De R. Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression. Biochim Biophys Acta Rev Cancer. 2025;1880(6):189471. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189471.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1842_CR85","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cytogfr.2025.10.001","volume":"86","author":"W Ma","year":"2025","unstructured":"Ma W, Morris S, Jamieson C. Reprogramming natural killer cells in the tumor microenvironment: challenges and therapeuticopportunities. Cytokine Growth Factor Rev. 2025;86:71\u201382. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1842_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2017.03.060","volume":"145","author":"MA Geller","year":"2017","unstructured":"Geller MA, Bendzick LA, Ryan C, Chu S, Lenvik A, Skubitz APN, et al. Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer. Gynecol Oncol. 2017;145:19. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.060.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1842_CR87","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.4110\/in.2025.25.e17","volume":"25","author":"B Marr","year":"2025","unstructured":"Marr B, Jo D, Jang M, Lee SH. Cytokines in focus: IL-2 and IL-15 in NK adoptive cell cancer immunotherapy. Immune Netw. 2025;25(2):e17. https:\/\/doi.org\/10.4110\/in.2025.25.e17.","journal-title":"Immune Netw"},{"issue":"1","key":"1842_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12943-025-02407-6","volume":"24","author":"Y Lv","year":"2025","unstructured":"Lv Y, Li Z, Liu S, Zhou Z, Song J, Ba Y, et al. Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy. Mol Cancer. 2025;24(1):210. https:\/\/doi.org\/10.1186\/s12943-025-02407-6.","journal-title":"Mol Cancer"},{"issue":"3","key":"1842_CR89","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity. 2024;57(3):414\u201328. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.001.","journal-title":"Immunity"},{"key":"1842_CR90","doi-asserted-by":"publisher","first-page":"1227064","DOI":"10.3389\/fimmu.2023.1227064","volume":"14","author":"M Sivonen","year":"2023","unstructured":"Sivonen M, Sirvi\u00f6 KA, Wojciechowski S, Kailaanm\u00e4ki A, Kaipainen S, Bailey A, et al. Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro. Front Immunol. 2023;14:1227064. https:\/\/doi.org\/10.3389\/fimmu.2023.1227064.","journal-title":"Front Immunol"},{"issue":"19","key":"1842_CR91","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186(19):4007\u201337. https:\/\/doi.org\/10.1016\/j.cell.2023.07.036.","journal-title":"Cell"},{"issue":"1","key":"1842_CR92","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","volume":"13","author":"J Zhu","year":"2022","unstructured":"Zhu J, Ke Y, Liu Q, Yang J, Liu F, Xu R, et al. Engineered lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. https:\/\/doi.org\/10.1038\/s41467-022-35130-7.","journal-title":"Nat Commun"},{"key":"1842_CR93","doi-asserted-by":"publisher","first-page":"1573635","DOI":"10.3389\/fimmu.2025.1573635","volume":"16","author":"W Chen","year":"2025","unstructured":"Chen W, Li Z, Tang J, Liu S. Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: advances and challenges. Front Immunol. 2025;16:1573635. https:\/\/doi.org\/10.3389\/fimmu.2025.1573635.","journal-title":"Front Immunol"},{"issue":"10","key":"1842_CR94","doi-asserted-by":"publisher","first-page":"728","DOI":"10.20892\/j.issn.2095-3941.2023.0241","volume":"20","author":"L Yang","year":"2023","unstructured":"Yang L, Li S, Chen L, Zhang Y. Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity. Cancer Biol Med. 2023;20(10):728\u201347. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0241.","journal-title":"Cancer Biol Med"},{"key":"1842_CR95","doi-asserted-by":"publisher","first-page":"109736","DOI":"10.1016\/j.intimp.2023.109736","volume":"116","author":"NJ Toney","year":"2023","unstructured":"Toney NJ, Gatti-Mays ME, Tschernia NP, Strauss J, Gulley JL, Schlom J, et al. Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12. Int Immunopharmacol. 2023;116:109736. https:\/\/doi.org\/10.1016\/j.intimp.2023.109736.","journal-title":"Int Immunopharmacol"},{"key":"1842_CR96","doi-asserted-by":"publisher","first-page":"1393451","DOI":"10.3389\/fimmu.2024.1393451","volume":"15","author":"MY Chen","year":"2024","unstructured":"Chen MY, Zhang F, Goedegebuure SP, Gillanders WE. Dendritic cell subsets and implications for cancer immunotherapy. Front Immunol. 2024;15:1393451. https:\/\/doi.org\/10.3389\/fimmu.2024.1393451.","journal-title":"Front Immunol"},{"issue":"5","key":"1842_CR97","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432\u201347. https:\/\/doi.org\/10.1038\/s41423-023-00990-6.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"1842_CR98","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molimm.2005.04.007","volume":"43","author":"JS Dela Cruz","year":"2006","unstructured":"Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Anti-HER2\/neu IgG3-(IL-2) and anti-HER2\/neu IgG3-(GM-CSF) promote HER2\/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol. 2006;43(6):667\u201376. https:\/\/doi.org\/10.1016\/j.molimm.2005.04.007.","journal-title":"Mol Immunol"},{"issue":"1","key":"1842_CR99","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang C, Jiang A, Lin A, Liu Z, Cheng X, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22(1):293. https:\/\/doi.org\/10.1186\/s12967-024-05104-y.","journal-title":"J Transl Med"},{"issue":"1","key":"1842_CR100","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12957-021-02299-y","volume":"19","author":"T Xue","year":"2021","unstructured":"Xue T, Yan K, Cai Y, Sun J, Chen Z, Chen X, et al. Prognostic significance of CD163\u2009+\u2009tumor-associated macrophages in colorectal cancer. World J Surg Oncol. 2021;19(1):186. https:\/\/doi.org\/10.1186\/s12957-021-02299-y.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"1842_CR101","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.3390\/cells9122665","volume":"9","author":"AJ Ali","year":"2020","unstructured":"Ali AJ, Makings J, Ley K. Regulatory T cell stability and plasticity in atherosclerosis. Cells. 2020;9(12):2665. https:\/\/doi.org\/10.3390\/cells9122665.","journal-title":"Cells"},{"issue":"8","key":"1842_CR102","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/2326-6066.CIR-18-0066","volume":"6","author":"AE Overacre-Delgoffe","year":"2018","unstructured":"Overacre-Delgoffe AE, Vignali DAA. Treg fragility: a prerequisite for effective antitumor immunity? Cancer Immunol Res. 2018;6(8):882\u20137. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0066.","journal-title":"Cancer Immunol Res"},{"key":"1842_CR103","doi-asserted-by":"publisher","unstructured":"Yp R, Re N, S J, L L, J D, D M, et al. Stability of the regulatory T cell lineage in vivo. Science. 2010;329(5999). https:\/\/doi.org\/10.1126\/science.1191996.","DOI":"10.1126\/science.1191996"},{"issue":"1","key":"1842_CR104","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022;15(1):104. https:\/\/doi.org\/10.1186\/s13045-022-01322-3.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1842_CR105","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"AE Overacre-Delgoffe","year":"2017","unstructured":"Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-\u03b3 drives treg fragility to promote anti-tumor immunity. Cell. 2017;169(6):1131\u2013e114111. https:\/\/doi.org\/10.1016\/j.cell.2017.05.005.","journal-title":"Cell"},{"issue":"3","key":"1842_CR106","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lazarus J, Steele NG, Yan W, Lee HJ, Nwosu ZC, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10(3):422\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0958.","journal-title":"Cancer Discov"},{"issue":"2","key":"1842_CR107","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41423-020-00599-z","volume":"18","author":"M Permanyer","year":"2021","unstructured":"Permanyer M, Bosnjak B, Glage S, Friedrichsen M, Floess S, Huehn J, et al. Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool. Cell Mol Immunol. 2021;18(2):398\u2013414. https:\/\/doi.org\/10.1038\/s41423-020-00599-z.","journal-title":"Cell Mol Immunol"},{"issue":"7930","key":"1842_CR108","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8\u2009+\u2009T cells. Nature. 2022;610(7930):161\u201372. https:\/\/doi.org\/10.1038\/s41586-022-05192-0.","journal-title":"Nature"},{"issue":"1","key":"1842_CR109","doi-asserted-by":"publisher","first-page":"9223","DOI":"10.1038\/s41467-025-64296-z","volume":"16","author":"T Wang","year":"2025","unstructured":"Wang T, Xu Y, Zhang Z, Wu Y, Chen L, Zheng X, et al. \u03b1TIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models. Nat Commun. 2025;16(1):9223. https:\/\/doi.org\/10.1038\/s41467-025-64296-z.","journal-title":"Nat Commun"},{"issue":"12","key":"1842_CR110","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-22-0295","volume":"10","author":"H Zhang","year":"2022","unstructured":"Zhang H, Tomar VS, Li J, Basavaraja R, Yan F, Gui J, et al. Protection of regulatory T cells from fragility and inactivation in the tumor microenvironment. Cancer Immunol Res. 2022;10(12):1491\u2013505. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0295.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"1842_CR111","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nm.2389","volume":"17","author":"M Dominguez-Villar","year":"2011","unstructured":"Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3\u2009+\u2009regulatory T cells in human autoimmune disease. Nat Med. 2011;17(6):673\u20135. https:\/\/doi.org\/10.1038\/nm.2389.","journal-title":"Nat Med"},{"issue":"7","key":"1842_CR112","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2326-6066.CIR-22-0705","volume":"11","author":"CJ Nirschl","year":"2023","unstructured":"Nirschl CJ, Brodkin HR, Domonkos C, Dwyer CJ, Hicklin DJ, Ismail N, et al. mWTX-330, an IL-12 INDUKINE molecule, activates and reshapes tumor-infiltrating CD8\u2009+\u2009T and NK cells to generate antitumor immunity. Cancer Immunol Res. 2023;11(7):962\u201377. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0705.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1842_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1651-7","volume":"64","author":"EJ Sayour","year":"2015","unstructured":"Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, et al. Increased proportion of FoxP3\u2009+\u2009regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64(4):419\u201327. https:\/\/doi.org\/10.1007\/s00262-014-1651-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1842_CR114","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/JTO.0b013e3181d60fd7","volume":"5","author":"K Shimizu","year":"2010","unstructured":"Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3\u2009+\u2009regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5(5):585\u201390. https:\/\/doi.org\/10.1097\/JTO.0b013e3181d60fd7.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1842_CR115","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-230X-9-65","volume":"9","author":"M Haas","year":"2009","unstructured":"Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65. https:\/\/doi.org\/10.1186\/1471-230X-9-65.","journal-title":"BMC Gastroenterol"},{"key":"1842_CR116","doi-asserted-by":"publisher","first-page":"105084","DOI":"10.1016\/j.oraloncology.2020.105084","volume":"112","author":"JH Cho","year":"2021","unstructured":"Cho JH, Lim YC. Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2021;112:105084. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105084.","journal-title":"Oral Oncol"},{"key":"1842_CR117","doi-asserted-by":"publisher","first-page":"1115556","DOI":"10.3389\/fmicb.2023.1115556","volume":"14","author":"S Xu","year":"2023","unstructured":"Xu S, Xiong Y, Fu B, Guo D, Sha Z, Lin X, et al. Bacteria and macrophages in the tumor microenvironment. Front Microbiol. 2023;14:1115556. https:\/\/doi.org\/10.3389\/fmicb.2023.1115556.","journal-title":"Front Microbiol"},{"issue":"1","key":"1842_CR118","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10(1):268. https:\/\/doi.org\/10.1038\/s41392-025-02325-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1842_CR119","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00281-023-00988-2","volume":"45","author":"P Sadhukhan","year":"2023","unstructured":"Sadhukhan P, Seiwert TY. The role of macrophages in the tumor microenvironment and tumor metabolism. Semin Immunopathol. 2023;45(2):187\u2013201. https:\/\/doi.org\/10.1007\/s00281-023-00988-2.","journal-title":"Semin Immunopathol"},{"key":"1842_CR120","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731. https:\/\/doi.org\/10.3389\/fimmu.2020.01731.","journal-title":"Front Immunol"},{"key":"1842_CR121","doi-asserted-by":"publisher","first-page":"114725","DOI":"10.1016\/j.intimp.2025.114725","volume":"156","author":"X Liu","year":"2025","unstructured":"Liu X, Jiang R, Xu Y, Xu X, Fang L, Gao G, et al. Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma. Int Immunopharmacol. 2025;156:114725. https:\/\/doi.org\/10.1016\/j.intimp.2025.114725.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1842_CR122","doi-asserted-by":"publisher","first-page":"e004561","DOI":"10.1136\/jitc-2022-004561","volume":"10","author":"CM Minnar","year":"2022","unstructured":"Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, et al. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer. 2022;10(6):e004561. https:\/\/doi.org\/10.1136\/jitc-2022-004561.","journal-title":"J Immunother Cancer"},{"key":"1842_CR123","doi-asserted-by":"publisher","first-page":"1755401","DOI":"10.3389\/fimmu.2026.1755401","volume":"17","author":"OV Kovaleva","year":"2026","unstructured":"Kovaleva OV, Sinyov VV, Rashidova MA, Malashenko OS, Gratchev A. Tumor-associated neutrophils in renal cell carcinoma. Front Immunol. 2026;17:1755401. https:\/\/doi.org\/10.3389\/fimmu.2026.1755401.","journal-title":"Front Immunol"},{"issue":"1","key":"1842_CR124","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","volume":"43","author":"H Luo","year":"2024","unstructured":"Luo H, Ikenaga N, Nakata K, Higashijima N, Zhong P, Kubo A, et al. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res CR. 2024;43(1):258. https:\/\/doi.org\/10.1186\/s13046-024-03178-6.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1842_CR125","doi-asserted-by":"publisher","first-page":"105087","DOI":"10.1016\/j.critrevonc.2025.105087","volume":"218","author":"J Wang","year":"2026","unstructured":"Wang J, Zhang M, Cui Z, Qu J, Chang R. Bidirectional role of neutrophils in lung cancer: mechanisms and therapeutic implications. Crit Rev Oncol Hematol. 2026;218:105087. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105087.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1842_CR126","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/2326-6066.CIR-23-0903","volume":"13","author":"S Wang","year":"2025","unstructured":"Wang S, Xu D, Wang Y, Zhou Y, Xiao L, Li F, et al. A bifunctional antibody targeting PD-1 and TGF-\u03b2 signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury. Cancer Immunol Res. 2025;13(5):767\u201384. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0903.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1842_CR127","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s13577-024-01024-7","volume":"37","author":"X Zhu","year":"2024","unstructured":"Zhu X, Heng Y, Zhang D, Tang D, Zhou J, Lin H, et al. Prognostic significance and immune escape implication of tumor-infiltrating neutrophil plasticity in human head and neck squamous cell carcinoma. Hum Cell. 2024;37(3):714\u201328. https:\/\/doi.org\/10.1007\/s13577-024-01024-7.","journal-title":"Hum Cell"},{"key":"1842_CR128","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.tranon.2023.101866","volume":"40","author":"S Zhang","year":"2024","unstructured":"Zhang S, Sun L, Zuo J, Feng D. Tumor associated neutrophils governs tumor progression through an IL-10\/STAT3\/PD-L1 feedback signaling loop in lung cancer. Transl Oncol. 2024;40:101866. https:\/\/doi.org\/10.1016\/j.tranon.2023.101866.","journal-title":"Transl Oncol"},{"issue":"4","key":"1842_CR129","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI37223","volume":"120","author":"J Jablonska","year":"2010","unstructured":"Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120(4):1151\u201364. https:\/\/doi.org\/10.1172\/JCI37223.","journal-title":"J Clin Invest"},{"issue":"8","key":"1842_CR130","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/ijc.29945","volume":"138","author":"L Andzinski","year":"2016","unstructured":"Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von K\u00f6ckritz-Blickwede M, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138(8):1982\u201393. https:\/\/doi.org\/10.1002\/ijc.29945.","journal-title":"Int J Cancer"},{"issue":"6","key":"1842_CR131","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s10238-023-00998-2","volume":"23","author":"L Zhu","year":"2023","unstructured":"Zhu L, Zhang X, Zhang S, Zhang Q, Cao L, Zhang Y, et al. Cancer-associated fibroblasts in papillary thyroid carcinoma. Clin Exp Med. 2023;23(6):2209\u201320. https:\/\/doi.org\/10.1007\/s10238-023-00998-2.","journal-title":"Clin Exp Med"},{"key":"1842_CR132","doi-asserted-by":"publisher","first-page":"1617662","DOI":"10.3389\/fimmu.2025.1617662","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo J, Xiang X, Gong G, Jiang L. Cancer-associated fibroblast-mediated immune evasion: molecular mechanisms of stromal-immune crosstalk in the tumor microenvironment. Front Immunol. 2025;16:1617662. https:\/\/doi.org\/10.3389\/fimmu.2025.1617662.","journal-title":"Front Immunol"},{"issue":"1","key":"1842_CR133","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","volume":"42","author":"G Mucciolo","year":"2024","unstructured":"Mucciolo G, Araos Henr\u00edquez J, Jihad M, Pinto Teles S, Manansala JS, Li W, et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 2024;42(1):101\u2013e11811. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.002.","journal-title":"Cancer Cell"},{"key":"1842_CR134","doi-asserted-by":"publisher","first-page":"1617968","DOI":"10.3389\/fimmu.2025.1617968","volume":"16","author":"M Wang","year":"2025","unstructured":"Wang M, Zhao Y, Xu K, Liu C, Zhong H, Wu Y, et al. Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities. Front Immunol. 2025;16:1617968. https:\/\/doi.org\/10.3389\/fimmu.2025.1617968.","journal-title":"Front Immunol"},{"issue":"3","key":"1842_CR135","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782\u201390. https:\/\/doi.org\/10.1002\/jcb.27681.","journal-title":"J Cell Biochem"},{"issue":"1","key":"1842_CR136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34. https:\/\/doi.org\/10.1186\/s13045-022-01252-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1842_CR137","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ijms22010238","volume":"22","author":"S Niland","year":"2020","unstructured":"Niland S, Eble JA. Hold on or cut? Integrin- and MMP-mediated cell-matrix interactions in the tumor microenvironment. Int J Mol Sci. 2020;22(1):238. https:\/\/doi.org\/10.3390\/ijms22010238.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1842_CR138","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1182\/blood-2002-10-3089","volume":"101","author":"P Hu","year":"2003","unstructured":"Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003;101(12):4853\u201361. https:\/\/doi.org\/10.1182\/blood-2002-10-3089.","journal-title":"Blood"},{"issue":"1","key":"1842_CR139","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2012.07.015","volume":"49","author":"S Gillessen","year":"2013","unstructured":"Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (selectikine) in patients with advanced solid tumors. Eur J Cancer. 2013;49(1):35\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.015.","journal-title":"Eur J Cancer"},{"key":"1842_CR140","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/BTT.S166310","volume":"13","author":"E Cruz","year":"2019","unstructured":"Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biol Targets Ther. 2019;13:33\u201351. https:\/\/doi.org\/10.2147\/BTT.S166310.","journal-title":"Biol Targets Ther"},{"issue":"5","key":"1842_CR141","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","volume":"13","author":"M Jain","year":"2007","unstructured":"Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(5):1374\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2436.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"1842_CR142","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00262-004-0624-7","volume":"54","author":"RJ Melder","year":"2005","unstructured":"Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother. 2005;54(6):535\u201347. https:\/\/doi.org\/10.1007\/s00262-004-0624-7.","journal-title":"Cancer Immunol Immunother"},{"key":"1842_CR143","doi-asserted-by":"publisher","unstructured":"Andersen JT, Sandlie I. Extending antibody fragment half-lives with albumin. In: Recombinant Antibodies for Immunotherapy. Cambridge: Cambridge University Press; 2009. p. 293-310. https:\/\/doi.org\/10.1017\/CBO9780511596773.023.","DOI":"10.1017\/CBO9780511596773.023"},{"issue":"15","key":"1842_CR144","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.3390\/cancers16152681","volume":"16","author":"VM Medina Perez","year":"2024","unstructured":"Medina Perez VM, Baselga M, Schuhmacher AJ. Single-domain antibodies as antibody-drug conjugates: from promise to practice-a systematic review. Cancers (Basel). 2024;16(15):2681. https:\/\/doi.org\/10.3390\/cancers16152681.","journal-title":"Cancers (Basel)"},{"key":"1842_CR145","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.biopha.2017.07.160","volume":"95","author":"Z Valedkarimi","year":"2017","unstructured":"Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Majidi J. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomed Pharmacother. 2017;95:731\u201342. https:\/\/doi.org\/10.1016\/j.biopha.2017.07.160.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1842_CR146","first-page":"3402","volume":"52","author":"T Yokota","year":"1992","unstructured":"Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52(12):3402\u20138. PMID:1596900.","journal-title":"Cancer Res"},{"issue":"5","key":"1842_CR147","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1593\/tlo.13409","volume":"6","author":"R Muchekehu","year":"2013","unstructured":"Muchekehu R, Liu D, Horn M, Campbell L, Del Rosario J, Bacica M, et al. The effect of molecular weight, PK, and valency on tumor biodistribution and efficacy of antibody-based drugs. Transl Oncol. 2013;6(5):562\u201372. https:\/\/doi.org\/10.1593\/tlo.13409.","journal-title":"Transl Oncol"},{"issue":"3","key":"1842_CR148","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1021\/bc00021a008","volume":"4","author":"SD Gillies","year":"1993","unstructured":"Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of anti-tumor antibody\/cytokine fusion proteins. Bioconjug Chem. 1993;4(3):231\u20135. https:\/\/doi.org\/10.1021\/bc00021a008.","journal-title":"Bioconjug Chem"},{"key":"1842_CR149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jbiotec.2018.12.004","volume":"291","author":"T Ongaro","year":"2019","unstructured":"Ongaro T, Matasci M, Cazzamalli S, Gouyou B, De Luca R, Neri D, et al. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. J Biotechnol. 2019;291:17\u201325. https:\/\/doi.org\/10.1016\/j.jbiotec.2018.12.004.","journal-title":"J Biotechnol"},{"issue":"9","key":"1842_CR150","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/ijc.22101","volume":"119","author":"V Gafner","year":"2006","unstructured":"Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer. 2006;119(9):2205\u201312. https:\/\/doi.org\/10.1002\/ijc.22101.","journal-title":"Int J Cancer"},{"issue":"1","key":"1842_CR151","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016;4(1):49\u201360. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0093-T.","journal-title":"Cancer Immunol Res"},{"key":"1842_CR152","doi-asserted-by":"publisher","first-page":"108750","DOI":"10.1016\/j.biopha.2019.108750","volume":"113","author":"AD AlQahtani","year":"2019","unstructured":"AlQahtani AD, O\u2019Connor D, Domling A, Goda SK. Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother. 2019;113:108750. https:\/\/doi.org\/10.1016\/j.biopha.2019.108750.","journal-title":"Biomed Pharmacother"},{"issue":"15suppl","key":"1842_CR153","doi-asserted-by":"publisher","first-page":"e14546","DOI":"10.1200\/JCO.2021.39.15_suppl.e14546","volume":"39","author":"MD To","year":"2021","unstructured":"To MD, Merchant F, Merchant N. MDNA11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates. J Clin Oncol. 2021;39(15suppl):e14546\u201314546. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e14546.","journal-title":"J Clin Oncol"},{"issue":"8 Suppl 2","key":"1842_CR154","doi-asserted-by":"publisher","first-page":"CT047","DOI":"10.1158\/1538-7445.AM2025-CT047","volume":"85","author":"VG Atkinson","year":"2025","unstructured":"Atkinson VG, Brenner W, Brown JT, Cabezon-Gutierrez L, Gajate P, Kim ST, et al. Interim results from the phase 1\/2 ABILITY-1 study of a long-acting beta-enhanced not-alpha IL-2 superkine in patients with advanced solid tumors. Cancer Res. 2025;85(8 Suppl 2):CT047\u2013047. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT047.","journal-title":"Cancer Res"},{"key":"1842_CR155","doi-asserted-by":"publisher","first-page":"1362775","DOI":"10.3389\/fimmu.2024.1362775","volume":"15","author":"RT Kenney","year":"2024","unstructured":"Kenney RT, Cini JK, Dexter S, DaFonseca M, Bingham J, Kuan I, et al. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers. Front Immunol. 2024;15:1362775. https:\/\/doi.org\/10.3389\/fimmu.2024.1362775.","journal-title":"Front Immunol"},{"issue":"5","key":"1842_CR156","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00262-003-0454-z","volume":"53","author":"Z Yao","year":"2004","unstructured":"Yao Z, Dai W, Perry J, Brechbiel MW, Sung C. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother CII. 2004;53(5):404\u201310. https:\/\/doi.org\/10.1007\/s00262-003-0454-z.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"5","key":"1842_CR157","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.medj.2023.03.007","volume":"4","author":"E Gutierrez","year":"2023","unstructured":"Gutierrez E, Bigelow M, LaCroix C, Beech J, Kirby P, Markowitz L, et al. An optimized IL-12-fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med N Y N. 2023;4(5):326\u2013e3405. https:\/\/doi.org\/10.1016\/j.medj.2023.03.007.","journal-title":"Med N Y N"},{"issue":"1","key":"1842_CR158","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1038\/s41467-025-59971-0","volume":"16","author":"M Beffinger","year":"2025","unstructured":"Beffinger M, Schellhammer L, Taskoparan B, Deplazes S, Salazar U, Tatari N, et al. FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nat Commun. 2025;16(1):4751. https:\/\/doi.org\/10.1038\/s41467-025-59971-0.","journal-title":"Nat Commun"},{"key":"1842_CR159","doi-asserted-by":"publisher","first-page":"1493257","DOI":"10.3389\/fimmu.2024.1493257","volume":"15","author":"JK Cini","year":"2024","unstructured":"Cini JK, Kenney RT, Dexter S, McAndrew SJ, Eraslan RN, Brody R, et al. SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. Front Immunol. 2024;15:1493257. https:\/\/doi.org\/10.3389\/fimmu.2024.1493257.","journal-title":"Front Immunol"},{"key":"1842_CR160","unstructured":"ClinicalTrials.gov. A phase 1 study of JS014, a recombinant fusion protein of interleukin-21 and humanized anti-human serum albumin VHH antibody as a single agent or in combination with pembrolizumab in subjects with advanced cancer. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05296772."},{"issue":"1","key":"1842_CR161","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","volume":"25","author":"J Strauss","year":"2019","unstructured":"Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(1):99\u2013109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1512.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"1842_CR162","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrc.2017.92","volume":"17","author":"N Gengenbacher","year":"2017","unstructured":"Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumor models: status quo, challenges and perspectives. Nat Rev Cancer. 2017;17(12):751\u201365. https:\/\/doi.org\/10.1038\/nrc.2017.92.","journal-title":"Nat Rev Cancer"},{"key":"1842_CR163","doi-asserted-by":"publisher","unstructured":"Park M, Shin K, Kim S, Lee H, Lee Y, Kim J, et al. GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocyte expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment. Regular and Young Investigator Award Abstracts. 2023;A1169-A1169. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.1062.","DOI":"10.1136\/jitc-2023-SITC2023.1062"},{"key":"1842_CR164","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","volume":"117","author":"L Mazzarella","year":"2019","unstructured":"Mazzarella L, Duso BA, Trapani D, Belli C, D\u2019Amico P, Ferraro E, et al. The evolving landscape of \u2018next-generation\u2019 immune checkpoint inhibitors: a review. Eur J Cancer. 2019;117:14\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.035.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1842_CR165","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1007\/s00253-013-5349-0","volume":"98","author":"L Ye","year":"2014","unstructured":"Ye L, Fan J, Shi X, Tao Q, Ye D, Xian Z, et al. Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo. Appl Microbiol Biotechnol. 2014;98(9):4053\u201361. https:\/\/doi.org\/10.1007\/s00253-013-5349-0.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"8","key":"1842_CR166","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595\u2013601. https:\/\/doi.org\/10.1038\/nri1901.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"1842_CR167","doi-asserted-by":"publisher","first-page":"e168224","DOI":"10.1172\/jci.insight.168224","volume":"8","author":"S Battula","year":"2023","unstructured":"Battula S, Papastoitsis G, Kaufman HL, Wittrup KD, Schmidt MM. Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment. JCI Insight. 2023;8(23):e168224. https:\/\/doi.org\/10.1172\/jci.insight.168224.","journal-title":"JCI Insight"},{"issue":"1","key":"1842_CR168","doi-asserted-by":"publisher","first-page":"2197360","DOI":"10.1080\/2162402X.2023.2197360","volume":"12","author":"L Codarri Deak","year":"2023","unstructured":"Codarri Deak L, Hashimoto M, Uma\u00f1a P, Klein C. Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2R\u03b2\u03b3-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition. Oncoimmunology. 2023;12(1):2197360. https:\/\/doi.org\/10.1080\/2162402X.2023.2197360.","journal-title":"Oncoimmunology"},{"issue":"16 Suppl","key":"1842_CR169","doi-asserted-by":"publisher","first-page":"e14505","DOI":"10.1200\/JCO.2024.42.16_suppl.e14505","volume":"42","author":"G Wu","year":"2024","unstructured":"Wu G, Ju D, Su Y, Yu H. Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. J Clin Oncol. 2024;42(16 Suppl):e14505\u201314505. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e14505.","journal-title":"J Clin Oncol"},{"key":"1842_CR170","doi-asserted-by":"publisher","unstructured":"Coward J, Kichenadasse G, Voskoboynik M, Frentzas S, Liu E, Cheng L, et al. Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti-PD-1\/IL-2 fusion protein, in patients with advanced tumors. J Immunother Cancer. 2025;13(Suppl 2):e0595. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.05951136\/jitc-2025-SITC2025.0595.","DOI":"10.1136\/jitc-2025-SITC2025.05951136\/jitc-2025-SITC2025.0595"},{"issue":"16suppl","key":"1842_CR171","doi-asserted-by":"publisher","first-page":"e14506","DOI":"10.1200\/JCO.2025.43.16_suppl.e14506","volume":"43","author":"A Tamir","year":"2025","unstructured":"Tamir A, Eraslan RN, O\u2019Mara E, Kumar G, Shuparski A, Ruppova K, et al. Multiomic evaluation of TEV-56278, a PD-1-targeted attenuated IL-2 molecule, in a human ex vivo tumor model and association with immune activation with enhanced effector CD8 T cell selectivity. J Clin Oncol. 2025;43(16suppl):e14506\u201314506. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14506.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1842_CR172","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","volume":"43","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bai X, Chen Y, Liang T, Wang H, Sun Y, et al. First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol. 2025;43(16 Suppl):8509\u20138509. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8509.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1842_CR173","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2025.43.16_suppl.104","volume":"43","author":"Z Lin","year":"2025","unstructured":"Lin Z, Bai X, Liang X, Chen Y, Wang H, Wang Y, et al. Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer. J Clin Oncol. 2025;43(16 Suppl):104\u2013104. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.104.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1842_CR174","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00262-024-03742-1","volume":"73","author":"YJ Park","year":"2024","unstructured":"Park YJ, Kim S, Bang H, Kang SC, Cho S, Park JE, et al. MB2033, an anti-PD-L1 x IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity. Cancer Immunol Immunother. 2024;73(8):157. https:\/\/doi.org\/10.1007\/s00262-024-03742-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1842_CR175","doi-asserted-by":"publisher","unstructured":"Cho BC, Shin S, Lee JL, Shim B, Lee H, Yun N, et al. Preliminary results of GII-101-P101 (KEYNOTE-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and\/or metastatic solid tumors. Regular and Young Investigator Award Abstracts. 2022;A751-A751. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0718.","DOI":"10.1136\/jitc-2022-SITC2022.0718"},{"issue":"16suppl","key":"1842_CR176","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2024.42.16_suppl.2598","volume":"42","author":"J Lee","year":"2024","unstructured":"Lee J, Cho BC, Lee JL, Lee JY, Ma WW, Adjei AA, et al. A first-in-human, phase 1\/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: initial results from dose escalation. J Clin Oncol. 2024;42(16suppl):2598\u20132598. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2598.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1842_CR177","doi-asserted-by":"publisher","first-page":"104291","DOI":"10.1016\/j.esmoop.2025.104291","volume":"10","author":"A Naing","year":"2025","unstructured":"Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, et al. First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. ESMO Open. 2025;10(3):104291. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104291.","journal-title":"ESMO Open"},{"issue":"8","key":"1842_CR178","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-23-2658","volume":"30","author":"S Peters","year":"2024","unstructured":"Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, et al. Obinutuzumab pretreatment as a novel approach to mitigate formation of anti-drug antibodies against cergutuzumab amunaleukin in patients with solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(8):1631\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2658.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1842_CR179","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpba.2015.05.029","volume":"114","author":"K Stubenrauch","year":"2015","unstructured":"Stubenrauch K, K\u00fcnzel C, Vogel R, Tuerck D, Schick E, Heinrich J. Epitope characterization of the ADA response directed against a targeted immunocytokine. J Pharm Biomed Anal. 2015;114:296\u2013304. https:\/\/doi.org\/10.1016\/j.jpba.2015.05.029.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1842_CR180","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/abt\/tbac031","volume":"6","author":"J Chen","year":"2023","unstructured":"Chen J, Shen Z, Jiang X, Huang Z, Wu C, Jiang D, et al. Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15\/IL15R\u03b1 complex. Antib Ther. 2023;6(1):38\u201348. https:\/\/doi.org\/10.1093\/abt\/tbac031.","journal-title":"Antib Ther"},{"key":"1842_CR181","doi-asserted-by":"publisher","first-page":"S646","DOI":"10.1016\/j.annonc.2023.09.2213","volume":"34","author":"M Gutierrez","year":"2023","unstructured":"Gutierrez M, Garralda E, Calvo E, Van Dongen M, Eskens FA, Finlay M, et al. 1074TiP a phase I\/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors. Ann Oncol. 2023;34:S646\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2213.","journal-title":"Ann Oncol"},{"key":"1842_CR182","doi-asserted-by":"publisher","unstructured":"Naing A, Garralda E, Melichar B, Kotecki N, Prenen H, Grimaldi Y, et al. VICTORIA-01: a multicenter, open-label, phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced or metastatic solid tumors. Regular and Young Investigator Award Abstracts. 2024;A774-A774. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0675.","DOI":"10.1136\/jitc-2024-SITC2024.0675"},{"issue":"12 Suppl","key":"1842_CR183","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1158\/1538-7445.AM2022-3504","volume":"82","author":"I Tang","year":"2022","unstructured":"Tang I, Schwimmer L, Jin M, Gu S, Prior WW, Capacio A, et al. QL415, a tumor targeted IL-15 fusion protein stimulating both lymphoid and myeloid immune cells for optimal anti-tumor immune response. Cancer Res. 2022;82(12 Suppl):3504\u20133504. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-3504.","journal-title":"Cancer Res"},{"issue":"13 Suppl","key":"1842_CR184","doi-asserted-by":"publisher","first-page":"CT227","DOI":"10.1158\/1538-7445.AM2021-CT227","volume":"81","author":"JJ Luke","year":"2021","unstructured":"Luke JJ, Olszanski AJ, Puzanov I, Lu D, Hackett A, Martomo S, et al. A phase 1 multiple ascending dose study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors. Cancer Res. 2021;81(13 Suppl):CT227\u2013227. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-CT227.","journal-title":"Cancer Res"},{"issue":"8","key":"1842_CR185","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1158\/2326-6066.CIR-24-0937","volume":"13","author":"M Desbois","year":"2025","unstructured":"Desbois M, Giffon T, Yakkundi P, Denson CR, Sekar K, Hart KC, et al. IGM-7354, an immunocytokine with IL15 fused to an anti-PD-L1 IgM, induces NK and CD8\u2009+\u2009T cell-mediated cytotoxicity of PD-L1-positive tumor cells. Cancer Immunol Res. 2025;13(8):1172\u201389. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0937.","journal-title":"Cancer Immunol Res"},{"key":"1842_CR186","doi-asserted-by":"publisher","first-page":"S635","DOI":"10.1016\/j.annonc.2023.09.2187","volume":"34","author":"N Kotecki","year":"2023","unstructured":"Kotecki N, Rottey S, Garralda E, Galvao V, De Miguel Luken MJ, Saavedra Santa Gadea O, et al. 1048P Phase I\/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer. Ann Oncol. 2023;34:S635. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2187.","journal-title":"Ann Oncol"},{"issue":"6","key":"1842_CR187","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00262-022-03331-0","volume":"72","author":"SA Martomo","year":"2023","unstructured":"Martomo SA, Patel J. Evaluation of the clinical molecule anti-human-PD-L1\/IL-15 KD033 in the human-PD-1\/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo. Cancer Immunol Immunother CII. 2023;72(6):1941\u201350. https:\/\/doi.org\/10.1007\/s00262-022-03331-0.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"8 Suppl 1","key":"1842_CR188","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1158\/1538-7445.AM2025-3118","volume":"85","author":"X Liu","year":"2025","unstructured":"Liu X, Fu F, Zhou S, Wu W, Wen H, Liu Y, et al. IBI3026, a first-in-class anti-PD-1\/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment. Cancer Res. 2025;85(8 Suppl 1):3118\u20133118. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3118.","journal-title":"Cancer Res"},{"issue":"8Supplement1","key":"1842_CR189","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1158\/1538-7445.AM2025-1601","volume":"85","author":"S Dettling","year":"2025","unstructured":"Dettling S, Antoniolli M, P\u00e4tzold K, Gies M, Rosenhauer J, Liedke J, et al. Abstract 1601: advancing cancer immunotherapy: unveiling the potential of PD-L1-targeted IFN-\u03b12a dutaflip molecule through patient-derived tumor explants. Cancer Res. 2025;85(8Supplement1):1601. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-1601.","journal-title":"Cancer Res"},{"issue":"8Supplement1","key":"1842_CR190","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1158\/1538-7445.AM2025-4881","volume":"85","author":"J Li","year":"2025","unstructured":"Li J, Wang Y, Di M, Wu M, Feng X, Li Y, et al. Abstract 4881: a PD1-IFN\u03b1 fusion protein, with an attenuated IFN\u03b1 fused to a clinically validated PD1 mAb, elicited PD1-dependent IFN\u03b1 signaling and superior anti-tumor efficacy. Cancer Res. 2025;85(8Supplement1):4881. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-4881.","journal-title":"Cancer Res"},{"issue":"8 Suppl 1","key":"1842_CR191","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1158\/1538-7445.AM2025-3430","volume":"85","author":"C Gu","year":"2025","unstructured":"Gu C, Ding J, Ren B, Liang M, Ye L, Ou Y, et al. FP008, a novel anti-PD-1 x IL-10\u00a0M fusion protein for cancer therapy. Cancer Res. 2025;85(8 Suppl 1):3430\u20133430. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3430.","journal-title":"Cancer Res"},{"key":"1842_CR192","doi-asserted-by":"publisher","first-page":"1345473","DOI":"10.3389\/fimmu.2024.1345473","volume":"15","author":"MA Kroenke","year":"2024","unstructured":"Kroenke MA, Starcevic Manning M, Zuch de Zafra CL, Zhang X, Cook KD, Archer M, et al. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1\/IL-21 mutein fusion protein. Front Immunol. 2024;15:1345473. https:\/\/doi.org\/10.3389\/fimmu.2024.1345473.","journal-title":"Front Immunol"},{"issue":"12","key":"1842_CR193","first-page":"1951","volume":"2","author":"JA Hank","year":"1996","unstructured":"Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res. 1996;2(12):1951\u20139. PMID:9816154.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1842_CR194","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jnci\/89.21.1586","volume":"89","author":"HN Lode","year":"1997","unstructured":"Lode HN, Xiang R, Dolman CS, Reisfeld RA, Varki NM, Gillies SD. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. JNCI J Natl Cancer Inst. 1997;89(21):1586\u201394. https:\/\/doi.org\/10.1093\/jnci\/89.21.1586.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"23","key":"1842_CR195","first-page":"8498","volume":"61","author":"JM Ruehlmann","year":"2001","unstructured":"Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS, et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 2001;61(23):8498\u2013503. PMID:11731434.","journal-title":"Cancer Res"},{"issue":"10","key":"1842_CR196","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00262-018-2223-z","volume":"67","author":"MR Albertini","year":"2018","unstructured":"Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018;67(10):1647\u201358. https:\/\/doi.org\/10.1007\/s00262-018-2223-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1842_CR197","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1517\/13543780903048911","volume":"18","author":"BH Yamane","year":"2009","unstructured":"Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody -based immunotherapy with (EMD-273063) Hu14.18-IL2 in melanoma and neuroblastoma. Expert Opin Investig Drugs. 2009;18(7):991\u20131000. https:\/\/doi.org\/10.1517\/13543780903048911.","journal-title":"Expert Opin Investig Drugs"},{"issue":"33","key":"1842_CR198","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","volume":"28","author":"S Shusterman","year":"2010","unstructured":"Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a children\u2019s oncology group (COG) phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(33):4969\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.27.8861.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1842_CR199","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2407-13-20","volume":"13","author":"JP Connor","year":"2013","unstructured":"Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013;13:20. https:\/\/doi.org\/10.1186\/1471-2407-13-20.","journal-title":"BMC Cancer"},{"issue":"6","key":"1842_CR200","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-05-2000","volume":"12","author":"KL Osenga","year":"2006","unstructured":"Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the children\u2019s oncology group. Clin Cancer Res. 2006;12(6):1750\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2000.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1842_CR201","doi-asserted-by":"publisher","first-page":"803","DOI":"10.21037\/jgo.2020.04.02","volume":"11","author":"E Puca","year":"2020","unstructured":"Puca E, Schmitt-Koopmann C, Furter M, Murer P, Probst P, Dihr M, et al. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8\u2009+\u2009T cell in an immunocompetent mouse model of colorectal cancer. J Gastrointest Oncol. 2020;11(4):803\u201311. https:\/\/doi.org\/10.21037\/jgo.2020.04.02.","journal-title":"J Gastrointest Oncol"},{"issue":"39","key":"1842_CR202","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1016\/j.vaccine.2009.06.079","volume":"27","author":"YS Tsai","year":"2009","unstructured":"Tsai YS, Shiau AL, Chen YF, Tsai HT, Lee HL, Tzai TS, et al. Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model. Vaccine. 2009;27(39):5383\u201392. https:\/\/doi.org\/10.1016\/j.vaccine.2009.06.079.","journal-title":"Vaccine"},{"issue":"3","key":"1842_CR203","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ijc.28059","volume":"133","author":"M Vincent","year":"2013","unstructured":"Vincent M, Bessard A, Cochonneau D, Teppaz G, Sol\u00e9 V, Maillasson M, et al. Tumor targeting of the IL-15 superagonist RLI by an anti\u2010GD2 antibody strongly enhances its antitumor potency. Int J Cancer. 2013;133(3):757\u201365. https:\/\/doi.org\/10.1002\/ijc.28059.","journal-title":"Int J Cancer"},{"issue":"1","key":"1842_CR204","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2015.01.019","volume":"88","author":"S Wieckowski","year":"2015","unstructured":"Wieckowski S, Hemmerle T, Prince SS, Schlienger BD, Hillinger S, Neri D, et al. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. Lung Cancer Amst Neth. 2015;88(1):9\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.019.","journal-title":"Lung Cancer Amst Neth"},{"issue":"20","key":"1842_CR205","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1158\/1078-0432.CCR-07-5041","volume":"14","author":"J M\u00e5rlind","year":"2008","unstructured":"M\u00e5rlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, et al. Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy. Clin Cancer Res. 2008;14(20):6515\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5041.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1842_CR206","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antib12020029","volume":"12","author":"E Prodi","year":"2023","unstructured":"Prodi E, Comacchio C, Gilardoni E, Di Nitto C, Puca E, Neri D, et al. An antibody targeting fibroblast activation protein simultaneously fused to interleukin-2 and tumor necrosis factor selectively localizes to neoplastic lesions. Antibodies. 2023;12(2):29. https:\/\/doi.org\/10.3390\/antib12020029.","journal-title":"Antibodies"},{"issue":"1","key":"1842_CR207","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13046-024-03238-x","volume":"44","author":"C Carbone","year":"2025","unstructured":"Carbone C, De Luca R, Puca E, Agostini A, Caggiano A, Priori L, et al. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice. J Exp Clin Cancer Res. 2025;44(1):7. https:\/\/doi.org\/10.1186\/s13046-024-03238-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1\u20132","key":"1842_CR208","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4161\/19336918.2014.983785","volume":"9","author":"C Catania","year":"2015","unstructured":"Catania C, Maur M, Berardi R, Rocca A, Giacomo AMD, Spitaleri G, et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhes Migr. 2015;9(1\u20132):14\u201321. https:\/\/doi.org\/10.4161\/19336918.2014.983785.","journal-title":"Cell Adhes Migr"},{"issue":"16","key":"1842_CR209","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","volume":"46","author":"M Johannsen","year":"2010","unstructured":"Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. The tumor-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumors and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010;46(16):2926\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2010.07.033.","journal-title":"Eur J Cancer"},{"issue":"13","key":"1842_CR210","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","volume":"30","author":"N Steeghs","year":"2024","unstructured":"Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-S\u00f8rensen M, Robbrecht D, Tabernero J, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors. Clin Cancer Res. 2024;30(13):2693\u2013701. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3567.","journal-title":"Clin Cancer Res"},{"key":"1842_CR211","doi-asserted-by":"publisher","unstructured":"E MC, A SR, S S, Gv L, Mf S, A S, et al. Phase Ib study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and\/or metastatic melanoma. Cancer Res Commun. 2025;5(2). https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0601.","DOI":"10.1158\/2767-9764.CRC-24-0601"},{"issue":"4","key":"1842_CR212","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00262-006-0203-1","volume":"56","author":"KM Lo","year":"2006","unstructured":"Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, et al. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother CII. 2006;56(4):447\u201357. https:\/\/doi.org\/10.1007\/s00262-006-0203-1.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"7","key":"1842_CR213","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","volume":"17","author":"SM Rudman","year":"2011","unstructured":"Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, et al. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(7):1998\u20132005. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2490.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"1842_CR214","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-12-0019","volume":"11","author":"V Kermer","year":"2012","unstructured":"Kermer V, Baum V, Hornig N, Kontermann RE, M\u00fcller D. An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans -Presentation at the Tumor Site. Mol Cancer Ther. 2012;11(6):1279\u201388. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0019.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1842_CR215","doi-asserted-by":"publisher","first-page":"e0219313","DOI":"10.1371\/journal.pone.0219313","volume":"14","author":"AS Schmid","year":"2019","unstructured":"Schmid AS, Neri D. Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation. PLoS ONE. 2019;14(7):e0219313. https:\/\/doi.org\/10.1371\/journal.pone.0219313.","journal-title":"PLoS ONE"},{"issue":"10","key":"1842_CR216","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1158\/0008-5472.CAN-07-0283","volume":"67","author":"M Kaspar","year":"2007","unstructured":"Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 2007;67(10):4940\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0283.","journal-title":"Cancer Res"},{"issue":"6","key":"1842_CR217","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.juro.2010.07.030","volume":"184","author":"K Frey","year":"2010","unstructured":"Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol. 2010;184(6):2540\u20138. https:\/\/doi.org\/10.1016\/j.juro.2010.07.030.","journal-title":"J Urol"},{"issue":"8","key":"1842_CR218","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/protein\/gzq038","volume":"23","author":"R Sommavilla","year":"2010","unstructured":"Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C, Villa A, et al. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel PEDS. 2010;23(8):653\u201361. https:\/\/doi.org\/10.1093\/protein\/gzq038.","journal-title":"Protein Eng Des Sel PEDS"},{"issue":"9","key":"1842_CR219","doi-asserted-by":"publisher","first-page":"e005282","DOI":"10.1136\/jitc-2022-005282","volume":"10","author":"L Nadal","year":"2022","unstructured":"Nadal L, Peissert F, Elsayed A, Weiss T, Look T, Weller M, et al. Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody. J Immunother Cancer. 2022;10(9):e005282. https:\/\/doi.org\/10.1136\/jitc-2022-005282.","journal-title":"J Immunother Cancer"},{"issue":"15suppl","key":"1842_CR220","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.2020.38.15_suppl.2558","volume":"38","author":"P Roth","year":"2020","unstructured":"Roth P, Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, et al. Targeting glioblastoma with novel immunocytokines. J Clin Oncol. 2020;38(15suppl):2558\u20132558. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.2558.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1842_CR221","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","volume":"13","author":"MM van den Heuvel","year":"2015","unstructured":"van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AMC, De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;13(1):32. https:\/\/doi.org\/10.1186\/s12967-015-0397-0.","journal-title":"J Transl Med"},{"key":"1842_CR222","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-11-5","volume":"11","author":"J Laurent","year":"2013","unstructured":"Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C, et al. T-cell activation by treatment of cancer patients with EMD 521873 (selectikine), an IL-2\/anti-DNA fusion protein. J Transl Med. 2013;11:5. https:\/\/doi.org\/10.1186\/1479-5876-11-5.","journal-title":"J Transl Med"},{"key":"1842_CR223","doi-asserted-by":"publisher","unstructured":"Minnar C, Chariou P, Hicks K, Schlom J, Gameiro S. 605 NHS-IL12 plus entinostat combination effectively targets anti-PD-1\/PD-L1 checkpoint resistant murine tumors harboring MHC class I and antigen processing machinery deficiency. Regular and Young Investigator Award Abstracts. 2021:A635-A635. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.605.","DOI":"10.1136\/jitc-2021-SITC2021.605"},{"issue":"5","key":"1842_CR224","doi-asserted-by":"publisher","first-page":"e005813","DOI":"10.1136\/jitc-2022-005813","volume":"11","author":"J Strauss","year":"2023","unstructured":"Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, et al. First-in-human phase ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023;11(5):e005813. https:\/\/doi.org\/10.1136\/jitc-2022-005813.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1842_CR225","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","volume":"26","author":"SN Quayle","year":"2020","unstructured":"Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, Histed A, et al. CUE-101, a novel E7-pHLA-IL2-fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(8):1953\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3354.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1842_CR226","doi-asserted-by":"publisher","unstructured":"Puram S, Oppelt PJ, Ley JC, Zaretsky JM, Jackson R, Pipkorn P, et al. Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16-positive oropharyngeal squamous cell carcinoma. J Clin Oncol. 2025;43(16 Suppl):e18086. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e18086.","DOI":"10.1200\/JCO.2025.43.16_suppl.e18086"},{"issue":"16suppl","key":"1842_CR227","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1200\/JCO.2023.41.16_suppl.6013","volume":"41","author":"CH Chung","year":"2023","unstructured":"Chung CH, Colevas ADD, Adkins D, Rodriguez CP, Park JC, Gibson MK, et al. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent\/metastatic HPV16\u2009+\u2009head and neck cancer. J Clin Oncol. 2023;41(16suppl):6013\u20136013. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6013.","journal-title":"J Clin Oncol"},{"key":"1842_CR228","doi-asserted-by":"publisher","unstructured":"Girgis N, Christie Y, Merazga Z, Hatfield S, Histed A, Zhao F, et al. CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies. Regular and Young Investigator Award Abstracts. 2022;A1374-A1374. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1323.","DOI":"10.1136\/jitc-2022-SITC2022.1323"},{"key":"1842_CR229","doi-asserted-by":"publisher","unstructured":"Eva Selfridge J, Uboha N, Saenger Y, Chaves J, Zheng L, Powderly J, et al. A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201-positive patients with WT1-positive recurrent\/metastatic cancers. Regular and Young Investigator Award Abstracts. 2023;A846-A846. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0750.","DOI":"10.1136\/jitc-2023-SITC2023.0750"},{"issue":"7 Suppl","key":"1842_CR230","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1158\/1538-7445.AM2023-2935","volume":"83","author":"MC Poffenberger","year":"2023","unstructured":"Poffenberger MC, Bishop JL, Blackler RJ, Rowse G, Davies RH, Spreter von Kreudenstein T. ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity. Cancer Res. 2023;83(7 Suppl):2935\u20132935. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2935.","journal-title":"Cancer Res"},{"issue":"16suppl","key":"1842_CR231","doi-asserted-by":"publisher","first-page":"e14697","DOI":"10.1200\/JCO.2024.42.16_suppl.e14697","volume":"42","author":"H Zhou","year":"2024","unstructured":"Zhou H, Li Z, Zhang F, Zhang Z. Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism. J Clin Oncol. 2024;42(16suppl):e14697\u201314697. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e14697.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1842_CR232","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1158\/1535-7163.MCT-23-0336","volume":"23","author":"E Patel","year":"2024","unstructured":"Patel E, Malkova NV, Crowe D, Pederzoli-Ribeil M, Fantini D, Fanny M, et al. XTX301, a tumor-activated interleukin-12 has the potential to widen the therapeutic index of IL12 treatment for solid tumors as evidenced by preclinical studies. Mol Cancer Ther. 2024;23(4):421\u201335. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0336.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1842_CR233","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi W, Liu N, Liu Z, Yang Y, Zeng Q, Wang Y, et al. Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep Med. 2024;5(5):101531. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101531.","journal-title":"Cell Rep Med"},{"key":"1842_CR234","doi-asserted-by":"publisher","unstructured":"Li Z, Zhang F, Zhang Z, Zhou H. PTX912, a first-in-class PD-1\/proIL-2 fusion protein, exhibits PD-1 blockade and tumor-activated IL-2R agonism for effective cancer immunotherapy with enhanced therapeutic window. Regular and Young Investigator Award Abstracts. 2024;A1083-A1083. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0967.","DOI":"10.1136\/jitc-2024-SITC2024.0967"},{"key":"1842_CR235","doi-asserted-by":"publisher","unstructured":"Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, et al. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies. Cell Rep Med. 2024;5(10):101747. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101747.","DOI":"10.1016\/j.xcrm.2024.101747"},{"key":"1842_CR236","doi-asserted-by":"publisher","unstructured":"Zhang J, Li J, Yin X, Shan J, Wu L, Ren X, et al. Initial safety and efficacy results from a first-in-human, phase 1\/2 study of ASKG915, an anti-PD-1\/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors. J Immunother Cancer. 2025;13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.06161136\/jitc-2025-SITC2025.0616.","DOI":"10.1136\/jitc-2025-SITC2025.06161136\/jitc-2025-SITC2025.0616"},{"issue":"12Supplement","key":"1842_CR237","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/1538-7445.AM2022-3505","volume":"82","author":"NK Mehta","year":"2022","unstructured":"Mehta NK, Li B, Rakhra K, Wittrup KD, Baeuerle PA, Michaelson JS. Abstract 3505: CLN-617 is an IL-2\/IL-12 fusion protein with a collagen-anchoring domain that induces potent systemic anti-tumor immunity upon intra-tumoral administration. Cancer Res. 2022;82(12Supplement):3505\u20133505. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-3505.","journal-title":"Cancer Res"},{"issue":"7Supplement","key":"1842_CR238","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1158\/1538-7445.AM2023-1839","volume":"83","author":"NK Mehta","year":"2023","unstructured":"Mehta NK, Rakhra K, Meetze K, Wittrup KD, Michaelson JS, Baeuerle PA. Abstract 1839: CLN-617 is a first-in-class fusion protein that retains IL-2 and IL-12 in the injected tumor and potently triggers systemic anti-tumor immunity. Cancer Res. 2023;83(7Supplement):1839. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-1839.","journal-title":"Cancer Res"},{"issue":"8","key":"1842_CR239","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2326-6066.CIR-23-0636","volume":"12","author":"NK Mehta","year":"2024","unstructured":"Mehta NK, Rakhra K, Meetze KA, Li B, Momin N, Chang JYH, et al. CLN-617 retains IL2 and IL12 in injected tumors to drive robust and systemic immune-mediated antitumor activity. Cancer Immunol Res. 2024;12(8):1022\u201338. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0636.","journal-title":"Cancer Immunol Res"},{"key":"1842_CR240","doi-asserted-by":"publisher","first-page":"1326927","DOI":"10.3389\/fimmu.2023.1326927","volume":"14","author":"JK Cini","year":"2023","unstructured":"Cini JK, Dexter S, Rezac DJ, McAndrew SJ, Hedou G, Brody R, et al. SON-1210 - a novel bifunctional IL-12 \/ IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. Front Immunol. 2023;14:1326927. https:\/\/doi.org\/10.3389\/fimmu.2023.1326927.","journal-title":"Front Immunol"},{"issue":"11","key":"1842_CR241","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-17-0211","volume":"16","author":"R De Luca","year":"2017","unstructured":"De Luca R, Soltermann A, Pretto F, Pemberton-Ross C, Pellegrini G, Wulhfard S, et al. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy. Mol Cancer Ther. 2017;16(11):2442\u201351. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0211.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1842_CR242","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/15321819.2025.2538025","volume":"46","author":"GM Leclerc","year":"2025","unstructured":"Leclerc GM, Egan JO, You L, Shrestha N, Rhode PR, Wong HC. Development of analytical methods for detection of anti-drug antibodies neutralizing IL-15 and TGF-\u03b2 RII activity. J Immunoass Immunochem. 2025;46(5):491\u2013518. https:\/\/doi.org\/10.1080\/15321819.2025.2538025.","journal-title":"J Immunoass Immunochem"},{"issue":"4","key":"1842_CR243","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12032-015-0586-y","volume":"32","author":"H Cheng","year":"2015","unstructured":"Cheng H, Ye X, Chang X, Ma R, Cong X, Niu Y, et al. Construction, expression, and function of 6B11ScFv-mIL-12, a fusion protein that attacks human ovarian carcinoma. Med Oncol. 2015;32(4):130. https:\/\/doi.org\/10.1007\/s12032-015-0586-y.","journal-title":"Med Oncol"},{"key":"1842_CR244","doi-asserted-by":"publisher","unstructured":"Huang Z, Huang J, Ye F, Chen S, Huang D, Hua M, et al. A highly potent anti-LAG-3-IL-2c that selectively targets tumor-specific CD8+ T cells. Regul Young Investigator Award Abstracts. 2022;A1130-A1130. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1088.","DOI":"10.1136\/jitc-2022-SITC2022.1088"},{"issue":"Suppl 2","key":"1842_CR245","doi-asserted-by":"publisher","first-page":"A1230","DOI":"10.1136\/jitc-2022-SITC2022.1183","volume":"10","author":"K Shanebeck","year":"2022","unstructured":"Shanebeck K, Yu C, Yu S, Sun J, Wang D, Luiz J, et al. ASKG915 - an anti-PD-1 antibody-IL-15 prodrug fusion molecule with enhanced therapeutic potentials. J Immunother Cancer. 2022;10(Suppl 2):A1230\u20131230. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1183.","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01842-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:49:21Z","timestamp":1788666561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01842-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":245,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01842-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"75"}}